Abstract
PurposeTo analyze the prognostic value and potential target for therapeutic intervention of enhancer of zeste homologue 2 (EZH2) in uveal melanomas (UM) patients.MethodWe analyzed EZH2 expression in 89 primary UM patients by immuno- histochemistry to observe the clinicopathological and prognostic value of EZH2.ResultsThe high levels of mitoses count and Ki67 labeling index had significant correlation with overexpression EZH2 (R = 0.408, PConclusionOur critical finding is that overexpression EZH2 in UM can be served as predictive marker and is associated with adverse clinical outcomes. Further observation of EZH2 as a potential therapeutic target in UM is necessary.
Highlights
Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults
High level of enhancer of zeste homologue 2 (EZH2) expression was significantly associated with increased risk of distant metastasis by the Cox proportional hazards regression model and shorter UM-specific survival
Our critical finding is that overexpression EZH2 in UM can be served as predictive marker and is associated with adverse clinical outcomes
Summary
Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults. Molecular studies have shown that cluster differentiation could be made, classifying tumors according to their low and high risk of metastasis. The poor outcome of UM was related with overexpression of high mobility group A1 protein (HMGA1) [9]. Genetic studies reported the loss of chromosome 3 was the risk factor of poor outcome of UM [10, 11]. None of the above indicators can be considered as effectively therapeutic targets in UM except HMGA1. It is worth identifying reliable biomarkers of uveal melanoma for its early diagnosis and effective therapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
